stand < standard < standardisation

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by standard

Number of relevant bibliographic references: 146.
[20-40] [0 - 20][0 - 50][40-60]

Ident.	Authors (with country if any)	Title
000934 (2019)	George W. Reed [États-Unis] ; Robert A. Gerber [États-Unis] ; Ying Shan [États-Unis] ; Liza Takiya [États-Unis] ; Kimberly J. Dandreo [États-Unis] ; David Gruben [États-Unis] ; Joel Kremer [États-Unis] ; Gene Wallenstein [États-Unis]	Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
000A34 (2019)	Marco Sciveres [Italie] ; Silvia Nastasio [États-Unis] ; Giuseppe Maggiore [Italie]	Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis
000A43 (2019)	Miriam Cabello-Olmo ; Miriam Ara A ; Ilian Radichev ; Paul Smith ; Eduardo Huarte ; Miguel Barajas	New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes
000A64 (2019)	Masayoshi Harigai [Japon] ; Michi Tsutsumino [Japon] ; Hideto Takada [Japon] ; Kenji Nagasaka [Japon]	Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis.
000B15 (2019)	Matthew P. Banegas [États-Unis] ; Donna R. Rivera [États-Unis] ; Maureen C. O Eeffe-Rosetti [États-Unis] ; Nikki M. Carroll [États-Unis] ; Pamala A. Pawloski [États-Unis] ; David C. Tabano [États-Unis] ; Mara M. Epstein [États-Unis] ; Kai Yeung [États-Unis] ; Mark C. Hornbrook [États-Unis] ; Christine Lu [États-Unis] ; Debra P. Ritzwoller [États-Unis]	Long-term Patterns of Oral Anti-cancer Agent Adoption, Duration and Switching in Patients with CML
000B22 (2019)	Hossam Kamli ; Li Li ; Glenda C. Gobe	Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer
000B23 (2019)	Marialbert Acosta-Herrera [Espagne] ; Miguel A. González-Gay [Espagne] ; Javier Martín [Espagne] ; Ana Márquez [Espagne]	Leveraging Genetic Findings for Precision Medicine in Vasculitis
000B78 (2019)	Bogdan Batko [Pologne] ; Paulina Rolska-W Jcik [Pologne] ; Magdalena Władysiuk [Pologne]	Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review
000D06 (2019)	Kyle A. Dyson [États-Unis] ; Brian D. Stover [États-Unis] ; Adam Grippin [États-Unis] ; Hector R. Mendez-Gomez [États-Unis] ; Joanne Lagmay [États-Unis] ; Duane A. Mitchell [États-Unis] ; Elias J. Sayour [États-Unis]	Emerging trends in immunotherapy for pediatric sarcomas
000D61 (2019)	Line Uhrenholt [Danemark] ; Annette Schlemmer [Danemark] ; Ellen-Margrethe Hauge [Danemark] ; Robin Christensen [Danemark] ; Lene Dreyer [Danemark] ; Maria E. Suarez-Almazor [États-Unis] ; Salome Kristensen [Danemark]	Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
000D62 (2019)	Sun Yao [République populaire de Chine] ; Chen Jianlin [République populaire de Chine] ; Liu Yarong [République populaire de Chine] ; Li Botao [République populaire de Chine] ; Wang Qinghan [République populaire de Chine] ; Fang Hongliang [République populaire de Chine] ; Zhang Lu [République populaire de Chine] ; Ning Hongmei [République populaire de Chine] ; Wang Pin [République populaire de Chine, États-Unis] ; Chen Hu [République populaire de Chine] ; Hu Liangding [République populaire de Chine] ; Zhang Bin [République populaire de Chine]	Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
000D75 (2019)	Niels Graudal [Danemark] ; Benjamin Skov Kaas-Hansen [Danemark] ; Louise Guski [Danemark] ; Thorbj Rn Hubeck-Graudal [Danemark] ; Nicky J. Welton [Royaume-Uni] ; Gesche Jürgens [Danemark]	Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis—A Network Meta-Analysis of 36 Randomized Controlled Trials
000D98 (2019)	Noelle Frey [États-Unis] ; David Porter [États-Unis]	Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.
000E05 (2019)	Dawn Swan ; Kevin Lynch ; Mark Gurney ; Michael O Wyer	Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
000E18 (2019)	Thomas E. Delea [États-Unis] ; Xinke Zhang [États-Unis] ; Jordan Amdahl [États-Unis] ; Diana Boyko [États-Unis] ; Franziska Dirnberger [Suisse] ; Marco Campioni [Suisse] ; Ze Cong [États-Unis]	Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
000E89 (2019)	Romeo G. Mih Il [Roumanie]	Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
000F25 (2019)	Manabu Araki [Japon]	Blockade of IL-6 signaling in neuromyelitis optica.
000F28 (2019)	Dominik Samotij [Pologne] ; Adam Reich [Pologne]	Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
000F68 (2019)	Acharya Balkrishna [Inde] ; Sachin Shridhar Sakat [Inde] ; Kheemraj Joshi [Inde] ; Sandeep Paudel [Inde] ; Deepika Joshi [Inde] ; Kamal Joshi [Inde] ; Ravikant Ranjan [Inde] ; Abhishek Gupta [Inde] ; Kunal Bhattacharya [Inde, États-Unis] ; Anurag Varshney [Inde]	Anti-Inflammatory and Anti-Arthritic Efficacies of an Indian Traditional Herbo-Mineral Medicine “Divya Amvatari Ras” in Collagen Antibody-Induced Arthritis (CAIA) Mouse Model Through Modulation of IL-6/IL-1β/TNF-α/NFκB Signaling
001007 (2019)	Maurizio Marvisi [Italie] ; Sara Ramponi [Italie] ; Laura Balzarini [Italie] ; Chiara Mancini [Italie]	A “Crazy Paving” Pattern on CT Scan in a Patient Treated with Pembrolizumab
001076 (2018)	F. Proft [Allemagne] ; H. Schulze-Koops [Allemagne] ; M. Grunke [Allemagne] ; E. Schrezenmeier [Allemagne] ; F. Halleck [Allemagne] ; J. Henes [Allemagne] ; L. Unger [Allemagne] ; E. Schmidt [Allemagne] ; C. Fiehn [Allemagne] ; A. Jacobi [Allemagne] ; C. Iking-Konert [Allemagne] ; C. Kneitz [Allemagne] ; R E Schmidt [Allemagne] ; B. Bannert [Allemagne] ; R E Voll [Allemagne] ; R. Fischer-Betz [Allemagne] ; I. Kötter [Allemagne] ; H P Tony [Allemagne] ; J. Holle [Allemagne] ; M. Aringer [Allemagne] ; A. Erler [Allemagne] ; F. Behrens [Allemagne] ; G R Burmester [Allemagne] ; T. Dörner [Allemagne]	[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "standard" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "standard" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    standard
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021